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Human immunodeﬁciency virus type 1 nucleocapsid (NC) basic residues presumably contribute to
virus assembly via RNA, which serves as a scaffold for Gag–Gag interaction during particle assembly.
To determine whether NC basic residues play a role in Gag cleavage (thereby impacting virus assem-
bly), Gag processing efﬁciency and virus particle production were analyzed for an HIV-1 mutant
NC15A, with alanine serving as a substitute for all NC basic residues. Results indicate that NC15A sig-
niﬁcantly impaired virus maturation in addition to signiﬁcantly affecting Gag membrane binding
and assembly. Interestingly, removal of the matrix (MA) central globular domain ameliorated the
NC15A assembly and processing defects, likely through enhancement of Gag multimerization and
membrane binding capacities.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In most retroviruses, Gag precursor polypeptide expression is
sufﬁcient for mediating virus particle assembly [1]. During or soon
after virus budding, HIV-1 Gag precursor Pr55 is cleaved by viral
protease (PR) into matrix (MA; p17), capsid (CA; p24), nucleocap-
sid (NC; p7) and p6 domains [1,2]. This PR-mediated virus mat-
uration process is essential for acquiring viral infectivity [3–6]. In
addition to PR, enzymes required for virus replication are encoded
by pol. Due to its partial overlap with the gag coding sequence,
HIV-1 Pol polypeptide is initially translated as a Gag-Pol fusion
protein via a ribosomal frameshifting event occurring at a
frequency of approximately 5% [7], resulting in a Gag-Pol/Gag
expression ratio of approximately 1:20. Maintenance of a low
PR-associated Gag-Pol expression level is considered critical, since
the artiﬁcial overexpression of Gag-Pol or PR triggers reducedvirion yield due to the enhanced cleavage of Gag precursors prior
to virus assembly [8–14].
In addition to playing a key role in mediating viral genomic RNA
packaging, NC contains an interaction domain that promotes
Gag–Gag interaction [15–18]. Speciﬁc NC mutations either reduce
overall virus particle production, or trigger the production of
low-density virus particles [1]. NC-associated RNA may serve as a
scaffold facilitating NC–NC interaction and Gag assembly [19–26].
Deleting the NC domain or decreasing the number of positively
charged NC residues via alanine replacement has been shown to
markedly reduce virion yields [17,18,27–29]; reduced virion yields
associated with NC mutants may also be attributed, at least in part,
to a release defect [30,31]. One research group has suggested that
decreased virion production tied to NC mutants is the result of
released particle instability following cell budding [28]. However,
results from a separate study indicate that HIV-1 PR activity inhi-
bition enhances virion production by NC-deletion mutants, sug-
gesting that substantial amounts of assembly-defective Gag
molecules are cleaved by PR prior to virus particle formation
[27]. Accordingly, Gag that is slowly assembled may be more sus-
ceptible to cleavage by PR, thus further reducing virus release.
Since NC possesses dimerization potential [21], it may contribute
to PR activation by promoting Gag-Pol dimerization. Although
results from an in vitro study suggest that the NC domain enhances
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tribution to Gag cleavage, if any, also impacts virus assembly.
We have two motivations for the present study: (a) to deter-
mine whether positively charged NC basic residues involved in
RNA binding are required for PR-mediated Gag cleavage, and (b)
to clarify whether the impacts of NC mutations on Gag cleavage
(if any) affect Gag assembly and virion yields. We found that block-
ing NC-RNA association via the alanine replacement of all NC basic
residues (NC15A) reduced Gag cleavage efﬁciency and signiﬁcantly
impaired Gag assembly. PR activity inhibition resulted in partial
restoration of NC15A virion yields, suggesting that the virion deﬁ-
cit was in part affected by PR activity. We also observed that
removal of the central MA globular domain (DMA) markedly
reduced NC15A-induced Gag assembly and processing defects.
2. Materials and methods
2.1. Plasmid construction
The NC15A, as described previously [33], had the 15 NC basic
NC residues replaced with alanines. The MA mutation was
constructed by deleting a fragment from nt 831 to nt 1147 and
replacing it with a SalI linker [34]. To construct substitution
mutants T26S and A28S, DNA fragments containing the point
mutations were ﬁrst generated by the mutation-containing
primers (T26S:50-CTATTAGATTCCGGAGCAGAT-30; A28S:50-TAGATA
CAGGATCCGATGATTAC-30) and a reverse primer, 2577-51 (50-ACT
GGTACAGTCTCAATAGGGCTAATG-30), using an Env-deﬁcient HIV-1
vector, HIVgpt [35] as template. Each of the resulting PCR products
was then used as a megaprimer for a second round of PCR by
using the forward primer G80 (50-ATGAGAGAACCAAGGGGAAGTG
TGA-30). The PCR products were then digested with Spe1 and BclI
and ligated into HIVgpt. As described previously, the DMA was
constructed by deleting a fragment from nt 831 to nt 1147 and
replacing it with a SalI linker [34]. The myristylation-minus
(Myr) mutant, in which the second glycine residue has been
replaced by alanine, blocks Gag membrane binding and virus pro-
duction [36]. Each of the gag mutations was also introduced into
a PR-inactivated HIV-1 expression vector, HIVgptD25 [14], yielding
a set of PR-defective versions. In D25, Arg is substituted for the PR
catalytic residue Asp [14]. All mutation constructs were analyzed
using restriction enzymes or DNA sequencing, and each mutation
was subcloned into the HIV-1 expression vector HIVgpt [35].
2.2. Cell culture and transfection
293T and cells were maintained in DMEM supplemented with
10% fetal calf serum. Twenty-four hours before transfection, con-
ﬂuent 293T cells were trypsinized, split 1:10, and seeded onto
10-cm dishes. For each construct, 293T cells were transfected with
20 lg plasmid DNA using the calcium phosphate precipitation
method, with addition of 50 lM chloroquine to enhance transfec-
tion efﬁciency.
2.3. Western immunoblot analysis
Unless otherwise indicated, cells and culture supernatants were
harvest for proteins analysis at 48–72 h post-transfection. Cell and
supernatant samples were prepared and subjected to Western
immunoblot analysis as described previously [42]. For detection of
HIV Gag proteins, the primary antibody was an anti-p24gag mono-
clonal antibody (mouse hybridoma clone 183-H12-5C) from ascites
used at a dilution of 1:5000. The secondary antibody was a sheep
anti-mouse horseradish peroxidase (HRP)-conjugated antibody
diluted at 1:15,000. An enhanced chemiluminescence (ECL) kit
(Pierce) was used to visualize the membrane-bound Gag proteins.2.4. Membrane ﬂotation assays
We followed the protocol as described previously [42]. Brieﬂy,
cells were pelleted and resuspended in TE buffer (10 mM Tris–
HCl, pH 7.4, 1 mM EDTA) containing 10% sucrose and Complete
Protease Inhibitor Cocktail (Roche). Cell suspensions were sub-
jected to sonication followed by low-speed centrifugation to
remove nuclei and cell debris. Postnuclear supernatant (200 ll)
was mixed with 1.3 ml 87.5% sucrose in TE buffer containing
Complete Protease Inhibitor Cocktail and placed on the bottom of
a centrifuge tube. Solutions of 7.5 ml 65% sucrose and 3 ml 10%
sucrose in TE buffer were layered on top of the 1.5 ml mixture.
The gradients were centrifuged at 100,000g for 16–18 h at 4 C
and then ten fractions were collected from the top of the centrifuge
tube. Proteins in each fraction were precipitated with ice-cold 10%
trichloroacetic acid (TCA) and analyzed by Western immunoblot.2.5. Velocity sedimentation analysis of cytoplasmic Gag proteins
As described previously [42] and above, postnuclear super-
natant (500 ll) was prepared and mixed with an equal amount
of TEN buffer (50 mM Tris–HCl, pH 7.4, 2 mM EDTA, 150 mM
NaCl) containing Complete Protease Inhibitor Cocktail. The mixture
was then centrifuged through a pre-made 25–45% discontinuous
sucrose gradient at 130,000g for 1 h. Five 0.8-ml fractions were
collected from the top of the centrifuge tubes. Proteins present in
aliquots of each fraction were precipitated with ice-cold 10% TCA
and subjected to Western blot analysis.
2.6. Virus-associated RNA quantiﬁcation
Virus-containing supernatants were collected and centrifuged
through a 20% sucrose cushion. Virus-associated RNA was then
puriﬁed using a QIAamp Viral RNA Mini Kit (QIAGEN). Viral RNA,
eluted in RNase-free buffer, was treated with RQ1 RNAase-free
DNase (Promega) at 37 C for 30 min. As described previously
[42], total viral RNA was then quantiﬁed using a RiboGreen RNA
Assay Kit (Invitrogen) according to the manufacturer’s protocols.
Ribosomal RNA provided in the assay kit was used to establish a
RNA standard curve in parallel. Ratios of RNA concentrations to
Gag immunoblot band density units were determined for each
mutant and normalized to that of wt in parallel experiments.
2.7. Statistical analysis
Differences between control (wt) and experimental (mutant)
groups were assessed using Student’s t-tests. Data are expressed
as mean ± standard deviation. Signiﬁcance was deﬁned as
⁄p < 0.05, ⁄⁄p < 0.01.
3. Results
3.1. NC positive charge neutralization signiﬁcantly affects HIV-1 Gag
assembly and processing
To determine whether NC basic residues are required for Gag
assembly and processing, we inserted a NC15A mutation (with
all NC basic amino acid residues replaced with alanine [17,35]) into
a HIV-1 proviral expression vector (Fig. 1A). Initial results indicate
barely detectable Gag products in culture supernatants following
the transient expression of NC15A in 293T cells, suggesting that
NC positive charge elimination signiﬁcantly reduced VLP yields.
Given the likelihood that the PR-mediated cleavage of assembly-
defective Gag molecules may contribute to virion decreases
[17,35], PR activity suppression may lead to increased VLP
Fig. 1. Assembly and processing of HIV-1 mutants containing alanine replacement of all NC basic residues. (A) Schematic representations of wild-type (WT) and recombinant
HIV-1 mutants. Indicated are the HIV-1 Gag protein domains MA (matrix), CA (capsid), NC (nucleocapsid), p6, and two spacer peptides SP1 and SP2. ‘‘xxxxxxxxxx’’ denotes all
NC basic residues replaced with alanines.DMA contains a replacement of 106 codons by 4 codons (in bold face), with myristylation andMA/CA cleavage signal retained. (B–D)
Suppression of PR activity alleviates the assembly defect incurred by positive nucleocapsid charge elimination. (B) 293T cells were transfected with 20 lg of designated
plasmid. T26S and A28S are PR point mutations triggering 4-fold and 50-fold reductions in PR activity, respectively [38]. At 48 h post-transfection, culture supernatants and
cells were collected and prepared for protein analysis as described in Section 2. Viral pellet samples corresponding to 50% of total samples (lanes 6–10) and cell lysate samples
corresponding to 5% of total samples (lanes 1–5) were fractionated using 10% SDS–PAGE and electroblotted onto nitrocellulose ﬁlters. HIV-1 Gag proteins were probed with a
mouse monoclonal antibody directed at p24CA. Positions of HIV Gag proteins Pr55, p41, and p24 are indicated. (C) 293T cells were transfected with wt or mutant plasmids. At
4 h post-transfection, cells were replated on three dish plates and either left untreated (lanes 1 and 4) or treated with the HIV-1 protease inhibitor (PI) saquinavir at
concentrations of 0.1 lM (lanes 2 and 5) or 1.0 lM (lanes 3 and 6). At 48–72 h post-transfection, cells and culture supernatant were collected, prepared, and subjected to
Western immunoblot analysis. (D) 293T cells were transfected with the PR-inactivated version (D25) of NC15A. At 48–72 h post-transfection, culture supernatants and cells
were collected and subjected to Western immunoblotting.
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in the presence of a PR inhibitor, and (b) via the expression of a
PR activity-diminished backbone resulting from a substitution
mutation (T26S or A28S) at the PR domain. The addition of T26S
and A28S resulted in 4-fold and 50-fold reductions in PR activity,
respectively [36]. As shown in Fig. 1, barely detectable VLP-associ-
ated NC15A became readily detectable when expressed in T26S or
A28S backbones (panel B, lanes 8–10). Similarly, barely detectable
VLP-associated NC15A became clearly detectable, and wt VLP
yields increased following treatment with saquinavir, a PR inhibi-
tor (Fig. 1C, lower panel, lanes 1–6). These results support the pro-
posal that reduced VLP yield associated with NC mutants is partly
due to assembly-defective Gag cleavage; further conﬁrmation
comes from NC mutant construct expression in a PR-inactivated(D25) vector (Fig. 1D, lane 3). Combined, our data suggest that
PR activity suppression was responsible for increased VLP yields
associated with assembly-defective NC15A.
3.2. MA removal alleviates NC15A assembly and processing defects
MA basic residues bind with RNA [37–40], which may affect
Gag–Gag or Gag–Pol/Gag–Pol interaction. We therefore tested the
impacts of MA deletion on Gag assembly and processing, and
repeatedly observed that NC15A exhibited a noticeable increase
in VLP yields following MA removal (Fig. 2A, lane 9 versus lane
10, and B). Notably, low but detectable NC15A VLPs were largely
immature—that is, virus-associated Gag remained unprocessed or
incompletely processed (lane 9). In contrast, mature virus-
Fig. 2. Removal of MA ameliorates NC15A assembly and processing defects. (A) 293T cells were transfected with indicated constructs. At 48 h post-transfection, cells and
culture supernatants were collected, prepared, and subjected toWestern immunoblotting probed with an anti-p24CA antibody. (B) Gag proteins frommedium or cell samples
were quantiﬁed by scanning mutant and wt p24gag-associated band densities from immunoblots. Ratios of total Gag protein levels in the media to those in cells were
determined for each construct and compared with wt release levels by dividing the release ratio for each mutant by the wt ratio in parallel experiments. Error bars indicate
standard deviation. ⁄p < 0.05. (C) 293T cells were transfected with indicated constructs. At 48–72 h post-transfection, culture supernatants and cells were collected and
subjected to Western immunoblotting. (D) Total Gag proteins (wt or mutant Gag precursor) from medium or cell samples were detected with an anti-p24CA monoclonal
antibody and quantiﬁed by scanning wt and mutant Gag precursor band densities from immunoblots. Ratios of Gag in media to Gag in cells were determined for each
construct, and compared with wt release levels as described above. Error bands indicate standard deviation. ⁄p < 0.05.
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detectable (Fig. 2A, lane 10). To minimize the impacts of PR activity
on VLP assembly, all constructs were expressed in the PR-in-
activated (D25) backbone. Our results also suggest that NC15A
VLP yields were signiﬁcantly enhanced by MA removal
(Fig. 2C and D).
Although NC15A and DMA/NC15A both exhibited similar levels
of unprocessed Gag precursor at 48 h post-transfection (Fig. 2A,
lanes 4 and 5), results from a time-course analysis of Gag process-
ing suggest that removal of the MA globular domain signiﬁcantly
enhanced NC15A Gag processing efﬁciency (Fig. 3). It is likely that
the Gag mutation that disrupts VLP assembly also affects Gag–Polmolecular interaction, which in turn impairs PR activation. To fur-
ther determine if MA removal impacts VLP release and maturation,
accumulated VLPs in supernatants were collected at different time
intervals following treatment with cycloheximide. Our results indi-
cate signiﬁcant increases in wt virus-associated Gag accumulation
at 4 and 8 h host-treatment, but not at 12 h, suggesting that most
VLP assembly and release in the Gag molecules was completed by
8 h post-treatment (Fig. 4). Likewise, we did not observe signiﬁcant
changes in virus-associated Gag cleavage proﬁles, suggesting that
PR quickly mediates virus maturation following virus budding.
Mutations at HIV-1 NC basic residues can lead to PR-dependent
virion instability, with virions tending to fall apart with little
Fig. 3. NC15A-meidated Gag processing efﬁciency is signiﬁcantly enhanced following removal of MA. 293T cells were transfected with designated constructs. At 4 h post-
transfection, equal amounts of cells were plated on three dishes. Cell were collected at 8, 16 or 24 h post-transfection and subjected to Western immunoblotting. Cellular
Pr55gag and p24gag levels were quantiﬁed by scanning immunoblot band densities. Ratios of p24gag to Pr55gag or to mutant Gag precursor were determined for each mutant
and normalized to those of the wt in parallel experiments. Values were derived from three independent experiments. Bars indicate standard deviations. ⁄p < 0.05.
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ited slight accumulation decreases rather than increases at 8 and
12 h. Some of mature wt VLPs might also be unstable after release,
which leads to a decrease accumulated VLPs at 12 h. A faster
release rate in DMA compared to the wt was not observed in
repeat independent experiments. However, we consistently
observed that DMA/NC15A exhibited faster virus release and pro-
cessing rates compared to NC15A.
3.3. MA deletion enhances NC15A membrane binding and
multimerization capacities
We performed velocity sedimentation centrifugation analyses
of cellular Gag molecules, using a myristylation-deﬁcient (myr-)
Gag mutant (defective in membrane binding and incapable of mul-
timerizing into high-molecular weight complexes) as a control
[34]. Results indicate that wt Gag and the assembly-competent
mutant DMA tended to be found in high-sucrose density fractions,while most myr- Gag was recovered in fractions 1 and 2 (Fig. 5);
this is in agreement with previously reported results [41,42]. We
consistently observed substantial shifts of NC15A to higher sucrose
density fractions following MA deletion (Fig. 5, panel 3 versus 4
from top), suggesting that MA removal mitigates the NC15A
multimerization defect, which is compatible with improved VLP
yields (Fig. 2). It should be noted that some slightly overexposed
blots were purposely presented to make it easier for readers to
see the detected signals. Not all of the Western blots shown in
the ﬁgures were used for quantiﬁcation.
Since membrane binding is required for efﬁcient Gag multimer-
ization, we searched for correlations between Gag membrane-
binding capacity and multimerization efﬁciency using membrane
ﬂotation assays for each mutant and wt as described in the
Section 2. As expected, approximately 70% of the intracellular wt
or DMA Gag was membrane-bound, compared to 10% of the
myr- Gag (Fig. 6); this is consistent with previous research results
[41,42]. Markedly decreased membrane-binding capacities were
Fig. 4. VLP release and processing kinetics 293T cells grown in 10 cm culture dishes in triplicate were transfected with the designated plasmid, pooled, and divided equally
onto four dish plates. At 16 h post-transfection, supernatants were collected and fed medium containing 30 lg/ml of cycloheximide. Cells and supernatants were collected at
0, 4, 8 and 12 h following cycloheximide treatment. Supernatants were pelleted through 20% sucrose cushions and subjected to Western immunoblotting (panel A). Gag
proteins were quantiﬁed by scanning p24gag-associated band densities from immunoblots. Densitometric units representing total Gag proteins in medium and the ratio of
p24gag to Pr55gag band densities were plotted against time (panels B and C, respectively).
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wt, but NC15A membrane binding capacity increased signiﬁcantly
following MA removal (Fig. 6B), which is compatible with improve-
ments in both Gag assembly and VLP yield (Figs. 2 and 5).
3.4. RNA binding is not sufﬁcient for efﬁcient virus assembly
Since RNA is required for efﬁcient Gag assembly, virus-associ-
ated total RNAs for the NC15A and DMA/NC15A mutants (allexpressed in the PR-inactivated [D25] backbone) were measured
and normalized to those of wt (D25) in parallel experiments.
Results indicate that RNA quantities in both mutants were signiﬁ-
cantly lower than that in the wt (Fig. 7). However, they still con-
tained measurable amounts of RNA, suggesting that the CA
domain and/or remaining MA and NC basic residues in the DMA
region may contribute to RNA association. No positive relation-
ships were noted between RNA packaging and VLP assembly
capacity in the assembly-defective mutants. For example, both
Fig. 5. Velocity sedimentation analysis of cytoplasmic Gag precursor complexes. 293T cells were transfected with 20 lg of the PR-inactivated versions of the indicated
plasmids. Two days post-transfection, cells were homogenized and their extracted cytoplasmic lysates centrifuged through 25%, 35% and 45% sucrose step gradients at
130,000g for 1 h. Fractions were collected from gradient tops, and fraction aliquots were subjected to 10% SDS–PAGE and probed with a monoclonal antibody directed at
p24CA. Total Gag proteins were quantiﬁed by scanning the immunoblot band densities of fractions 1–5. Multimerized Gag protein percentages were determined by dividing
multimerized Gag protein density units (fractions 3–5) by total Gag density units (fractions 1–5) and normalizing the results to that of the wt.
Fig. 6. Membrane ﬂotation centrifugation of HIV-1 Gag proteins. (A) 293T cells were transfected with PR-inactivated (D25) versions of the indicated constructs. Two days
post-transfection, cells were harvested and homogenized. Crude membrane extracted from cell lysates was subjected to equilibrium ﬂotation centrifugation as described in
Section 2. In all, 10 fractions were collected from top downwards; fraction aliquots were analyzed by Western immunoblotting using an anti-p24CA monoclonal antibody.
During ultracentrifugation, membrane-bound Gag proteins ﬂoated to the 10–65% sucrose interface. (B) Quantiﬁcation of membrane-bound Gag proteins. Total Gag proteins
were quantiﬁed by scanning the immunoblot band densities of fractions 1–10. Percentages of membrane-bound Gag proteins were determined by dividing the membrane-
bound Gag protein density unit (fractions 2–4) by total Gag protein density unit and multiplying by 100. Error bands indicate standard deviation. ⁄p < 0.05.
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but the former produced VLPs more efﬁciently than the latter.
Our results suggest that RNA binding is insufﬁcient for efﬁcient
virus assembly.
4. Discussion
Our data indicate that (a) eliminating HIV-1 NC positive charges
by replacing all NC basic residues with alanine (NC15A) produced asigniﬁcant defect in VLP assembly associated with reduced Gag
cleavage efﬁciency and membrane binding capacity, and (b)
removing the MA central globular domain signiﬁcantly reduced
NC15A-incurred assembly and processing defects. That NC15A still
contains measurable amounts of RNA provides further support for
the proposal that RNA association is insufﬁcient for efﬁcient Gag
assembly.
We noted that virus-associated NC15A signiﬁcantly increased
following PR activity inhibition, thus supporting the idea that a
Fig. 7. Relative levels of virus-associated RNA. 293T cells were transfected with PR-
inactivated (D25) versions of the indicated constructs. Virus-containing super-
natants were pelleted and resuspended in PBS buffer. About 40% of the resulting
suspensions were subjected to Western immunoblot analysis, and the remaining
suspensions were subjected to RNA extraction and quantiﬁcation as described in
Section 2. Ratios of RNA amounts to Gag protein levels obtained by quantifying
immunoblot band densities were determined for each mutant and normalized to
those of wt (D25) in parallel experiments. Bars indicate standard deviations.
⁄p < 0.05.
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delayed-assembly Gag mutants prior to assembly and cell budding
[29]. This may help explain our observation that virus-associated
NC15A was incompletely processed (Fig. 2A lane 9). Intracellular
NC15A Gag cleavage efﬁciency was also markedly reduced
(Fig. 3). Since PR activation is triggered by Gag-Pol dimerization,
the observed reduction in Gag cleavage efﬁciency suggests that
the NC15A mutation, which impairs Gag–Gag interaction, may also
affect Gag–Pol/Gag–Pol interaction. Improved NC15A assembly
and processing efﬁciency following MA removal is likely tied to
enhanced Gag assembly and Gag–Pol/Gag–Pol interaction.
In vitro, polypeptide NC-SP2-p6 cleavage by PR is signiﬁcantly
enhanced by RNA association [30], therefore NC association with
RNA may facilitate PR-mediated Gag cleavage. However, we
observed that barely detectable p24gag in NC15A transfectant
supernatant became readily detectable following the removal of
MA (Fig. 2A, lanes 9 versus 10), indicating that Gag can still be efﬁ-
ciently processed even if it lacks RNA binding capability, and sug-
gesting that RNA association is not essential for PR-mediated Gag
cleavage.
Although NC15A produced low levels of VLPs, substantial
amounts of NC15A Gag were capable of membrane binding and
multimerization (Figs. 5 and 6). It is likely that the low NC15A
VLP yields were largely due to a release defect. In support of this
hypothesis, Dussupt et al. found that HIV-1 NC basic residues play
a role in combination with p6gag in virus budding by recruiting
host ﬁssion machinery (ESCRT) to facilitate HIV-1 release [44,45].
Accordingly, substitution mutations at NC basic residues may con-
tribute to reduced NC15A VLP yields as a result of a release defect.
Further studies are required to test this possibility.
The inactivation of PR activity is known to restore VLP yields
associated with a NC-deleted (DNC) mutant to wt levels
[27,29]. However, we found that NC15A VLP levels were still
lower than that of the wt when Gag cleavage was blocked
(Fig. 2D). A possible explanation for these conﬂicting results
may be that the NC15A mutation induces interactions that impair
or delay Gag assembly processing, with potentially deleterious
interaction regions being removed from the DNC mutant. It is
also possible that NC domain binding to plasma membranes
may interfere with the NC15A Gag conformational changeprocess (from bent to straight), thus inhibiting Gag assembly
[43]. NC removal may support VLP assembly by allowing Gag to
be in a straight shape at the beginning of Gag assembly. These
scenarios may partly explain why DNC is capable of producing
VLPs at a wt level while NC15A is not.
Membrane association is required for HIV-1 Gag assembly and
virus particle production [46–49]. According to the myristyl switch
model of Gag membrane binding and multimerization [50–54],
Gag multimerization induces a conformational change that
exposes N-terminal myristic acid moiety, which is largely seques-
tered when Gag takes monomeric or lower-order oligomeric forms.
The exposed myristic acid promotes Gag membrane binding capac-
ity, which in turn enhances Gag multimerization. Further, removal
of the MA globular domain containing basic residues may enhance
Gag membrane-binding capacity, since MA loses that capacity once
RNA binds to those residues [38,40,55]. These scenarios may partly
explain why MA removal signiﬁcantly mitigates NC15A membrane
binding and assembly efﬁciency. However, the extent of improved
membrane binding and multimerization capacity does not com-
pletely account for the increased NC15A virion yields following
MA removal. In conclusion, our ﬁndings suggest that in addition
to Gag multimerization and membrane binding deﬁcits, a budding
defect makes a signiﬁcant contribution to poor NC15A virus parti-
cle production.
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